<DOC>
	<DOCNO>NCT01495351</DOCNO>
	<brief_summary>The combination PARP inhibitor ( ABT-888 ) proteasome inhibitor ( bortezomib ) demonstrate significant anti-myeloma effect preclinical lab animal study . The goal phase I trial evaluate patient relapse refractory multiple myeloma safety , toxicity profile tolerability ABT-888 ( Veliparib ) administer schedule include twice daily oral dose 14 day follow 1 week rest combination standard dose Bortezomib .</brief_summary>
	<brief_title>Study ABT-888 Combination With Bortezomib Dexamethasone Patients With Relapsed Refractory Myeloma</brief_title>
	<detailed_description>This dose-finding / dose escalation phase I trial ABT-888 ( Veliparib ) combination Bortezomib Dexamethasone patient relapse refractory multiple myeloma . ABT-888 give orally ( PO ) twice daily ( every 12 hour ) 14 day 21 day cycle . First dose give within 1 hour Bortezomib day 1 . Planned start dose 20 mg PO every 12 hour . Starting dose escalation plan MTD reach .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Confirmed diagnosis multiple myeloma . Measurable disease , accord International Myeloma Working Group criterion . ECOG performance status 0 , 1 2 . Patients must receive prior treatment MM relapse progress prior therapy ; limit number prior treatment regimen , prior treatment must complete 2 week prior registration . Prior exposure Bortezomib exclusion criterion long patient progress relapse receive within 3 month complete trt bortezomib Prior radiation , complete least 4 week prior registration , permit . Adequate marrow reserve , liver renal function patient history malignancy , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , prostate cancer stable PSA &gt; 3 year , solid tumour curatively treat evidence disease &gt; 5 year . Patients preexist grade 2 ( high ) sensory neuropathy grade 1 sensory neuropathy neuropathic pain . Pregnant lactating woman Patients receive concurrent treatment anticancer therapy investigational agent . Active uncontrolled infection Patient know document congenital acquire risk factor thromboembolic event Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>